Precision Optics (NASDAQ:POCI) Issues Quarterly Earnings Results, Beats Estimates By $0.09 EPS

Posted by Tristan Rich on Sep 28th, 2026

Precision Optics (NASDAQ:POCI – Get Free Report) released its earnings results on Monday. The company reported $0.03 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.09, FiscalAI reports. Precision Optics had a negative net margin of 17.03% and a negative return on equity of 37.47%. The firm had revenue of $8.77 million during the quarter, compared to analyst estimates of $7.10 million.

Precision Optics Stock Performance

Shares of POCI stock traded down $0.10 during mid-day trading on Monday, reaching $4.53. The stock had a trading volume of 98,116 shares, compared to its average volume of 38,368. Precision Optics has a 1-year low of $3.55 and a 1-year high of $6.15. The firm has a market cap of $49.56 million, a price-to-earnings ratio of -7.19 and a beta of 0.32. The company has a current ratio of 2.10, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. The business’s fifty day moving average is $4.36 and its 200-day moving average is $4.63.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the company. Wall Street Zen raised Precision Optics to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision Optics in a report on Wednesday, September 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Read Our Latest Analysis on Precision Optics

About Precision Optics

(Get Free Report)

Precision Optics Corporation, Inc (NASDAQ: POCI) designs and manufactures advanced optical and imaging systems, primarily for the medical device market. The company develops products used in minimally invasive surgery, including endoscopes, surgical cameras, and specialized visualization systems that help physicians view internal anatomy during diagnostic and therapeutic procedures.

Its product portfolio includes reusable and single-use endoscopes, three-dimensional imaging systems, fluorescence imaging technologies, and custom optical components and assemblies.